Alexandra Langlais nackt

Admin05.09.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

The median OS from randomisation was 14.

3001

Admin19.08.2021

Mesothelioma: Langlais, Alexandra

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

3209

Admin22.08.2021

France: Langlais, Alexandra

T group", Curie Institute, Paris, France.

4305

Admin11.07.2021

France: Langlais, Alexandra

METHODS: The French Biomarkers France database, which includes 17,664 patients, was used.

2202

Admin30.08.2021

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

RESULTS: Overall, 83 cases with BRAF mutant disease 66.

505

Admin17.08.2021

Mesothelioma: Langlais, Alexandra

4 Department of Thoracic Oncology, 54 Rue Henri Sainte Claire Deville, CHITS CH Sainte Musse, 83000 Toulon, France.

2405

Admin17.07.2021

Mesothelioma: Langlais, Alexandra

18 Department of Biochemistry, Nantes University Hospital, 9 Quai Moncousu, 44093 Nantes, France.

9709

Admin02.09.2021

France: Langlais, Alexandra

7 Thoracic Oncology Unit, CHU Grenoble Alpes, 38700 Grenoble, France.

6807

Admin10.07.2021

France: Langlais, Alexandra

19 Department of Thoracic Oncology, Montpellier Regional University Hospital, 34090 Montpellier, France.

8010

Alexandra Langlais nackt sorted by relevance